Pharma-Bio Serv chairman granted 20,000 stock options

Pharma-Bio Serv, Inc. reported an insider equity award for Chairman and director Kirk Michel.

Rhea-AI Filing Summary

Pharma-Bio Serv, Inc. reported an insider equity award for Chairman and director Kirk Michel. On January 10, 2026, he received a stock option covering 20,000 shares of common stock at an exercise price of $0.54 per share, expiring on January 10, 2031. The option vests in two equal installments on July 10, 2026 and July 10, 2027, meaning half of the option becomes exercisable on each of those dates.

Insider Trade Summary

Grant/Award: 20,000 shares

Grant/Award 1 txn

Insider MICHEL KIRK WHEELER

Role Chairman

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	20,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 20,000 contracts (Direct)

Footnotes (1)

1. F1. The option vested in two equal installments on July 10, 2026 and July 10, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pharma-Bio Serv (PBSV) report on this Form 4?

The company reported a stock option grant to Chairman and director Kirk Michel for 20,000 derivative securities linked to common stock.

What are the key terms of Kirk Michel’s Pharma-Bio Serv (PBSV) stock option?

The stock option covers 20,000 shares at an exercise price of $0.54 per share and expires on January 10, 2031.

How does the 20,000-share stock option for PBSV’s chairman vest?

The option vests in two equal installments, with half vesting on July 10, 2026 and the remaining half on July 10, 2027.

Is the PBSV chairman’s stock option held directly or indirectly?

The Form 4 indicates the 20,000 stock options are held with direct ownership by the reporting person.

How many derivative securities does the PBSV chairman own after this transaction?

After the reported transaction, the chairman beneficially owns 20,000 derivative securities in the form of stock options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/14/2026 - 08:49 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MICHEL KIRK WHEELER

(Last) (First) (Middle)

4101 GLENLOCH CIRCLE

(Street)

MATTHEWS NC 28105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pharma-Bio Serv, Inc. [ PBSV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman

3. Date of Earliest Transaction (Month/Day/Year)
01/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.54	01/10/2026		A		20,000		(1)	01/10/2031	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. The option vested in two equal installments on July 10, 2026 and July 10, 2027.

	/s/ Kirk Michel	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.